

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Epoprostenol. [Updated 2023 Dec 15]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Epoprostenol

Revised: December 15, 2023.

CASRN: 35121-78-9

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of epoprostenol during breastfeeding. The half-life of epoprostenol is 6 minutes or less. It is unlikely that clinically important amounts of epoprostenol are excreted into milk and absorbed by the breastfed infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Epoprostenol

CAS Registry Number

35121-78-9

Drug Class

Breast Feeding

Lactation

Milk, Human

Cardiovascular Agents

Prostaglandins, Synthetic

Vasodilator Agents